Blog

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Blog

Congratulations Dr. Jason Chiang, Giles Robinson, Dr. Aditi Bagchi & the members of the Brain Tumor program – Amar Gajjar

Photo from St. Jude Research / Twitter

Aug 1, 2023, 19:34

Congratulations Dr. Jason Chiang, Giles Robinson, Dr. Aditi Bagchi & the members of the Brain Tumor program – Amar Gajjar

Congratulations Dr. Jason Chiang, Giles Robinson, Dr.Aditi Bagch & the members of the Brain Tumor program who led a new socoety for neuro-oncology study defining HGG in infants and young children using an integrated histopathological & molecular diagnosis.

For article: Click here
Source: Amar Gajjar / Twitter

Aditi Bagch Amar Gajjar brain tumor cancer Giles Robinson Jason Chiang molecular diagnosis Neuro-Oncology OncoDaily Oncology

Aug 29, 2024, 17:26

Natasha Rekhtman: Chromothripsis-mediated Small Cell Lung Cancer

Aug 29, 2024, 17:23

Common Sense Oncology at ESMO24

Aug 29, 2024, 17:20

Apply for ESO’s Certificate of Advanced Studies in Lung Cancer

Aug 29, 2024, 17:19

EU Navigate helps implement interventions for older people with cancer and their caregivers across Europe - European Cancer Organisation

Aug 29, 2024, 17:16

Day in the Life of a Leukaemia PhD researcher - Manchester Cancer Research Centre

Aug 29, 2024, 17:12

Haemato-oncology highlights from EHA2024 Congress - Sharing Progress in Cancer Care

Aug 29, 2024, 17:06

ESMO announces Tumour-Agnostic Classifier and Screener in Annals of Oncology

Aug 29, 2024, 17:03

Effects of the bone ecosystem on metastatic Prostate Cancer evolution and treatment response - NCI Physical Sciences

Aug 29, 2024, 17:03

Suzanne Birdsey: Opportunity for a Senior Strategy Manager at CRUK

Aug 29, 2024, 17:01

Elad Sharon: Quite promising for c-MET over-expressing NSCLC

Aug 29, 2024, 16:59

Talha Badar: Overview of AML induction strategies

Aug 29, 2024, 16:56

Stephen Liu: Overview of outcomes with 1L osimertinib